Literature DB >> 24758919

The Lung Reporting and Data System (LU-RADS): a proposal for computed tomography screening.

Daria Manos1, Jean M Seely2, Jana Taylor3, Joy Borgaonkar4, Heidi C Roberts5, John R Mayo6.   

Abstract

Despite the positive outcome of the recent randomized trial of computed tomography (CT) screening for lung cancer, substantial implementation challenges remain, including the clear reporting of relative risk and suggested workup of screen-detected nodules. Based on current literature, we propose a 6-level Lung-Reporting and Data System (LU-RADS) that classifies screening CTs by the nodule with the highest malignancy risk. As the LU-RADS level increases, the risk of malignancy increases. The LU-RADS level is linked directly to suggested follow-up pathways. Compared with current narrative reporting, this structure should improve communication with patients and clinicians, and provide a data collection framework to facilitate screening program evaluation and radiologist training. In overview, category 1 includes CTs with no nodules and returns the subject to routine screening. Category 2 scans harbor minimal risk, including <5 mm, perifissural, or long-term stable nodules that require no further workup before the next routine screening CT. Category 3 scans contain indeterminate nodules and require CT follow up with the interval dependent on nodule size (small [5-9 mm] or large [≥ 10 mm] and possibly transient). Category 4 scans are suspicious and are subdivided into 4A, low risk of malignancy; 4B, likely low-grade adenocarcinoma; and 4C, likely malignant. The 4B and 4C nodules have a high likelihood of neoplasm simply based on screening CT features, even if positron emission tomography, needle biopsy, and/or bronchoscopy are negative. Category 5 nodules demonstrate frankly malignant behavior on screening CT, and category 6 scans contain tissue-proven malignancies.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LU-RADS; Low-dose computed tomography; Lung cancer screening; Lung nodules; National lung screening trial; Nodule risk

Mesh:

Year:  2014        PMID: 24758919     DOI: 10.1016/j.carj.2014.03.004

Source DB:  PubMed          Journal:  Can Assoc Radiol J        ISSN: 0846-5371            Impact factor:   2.248


  16 in total

1.  LUNGx Challenge for computerized lung nodule classification.

Authors:  Samuel G Armato; Karen Drukker; Feng Li; Lubomir Hadjiiski; Georgia D Tourassi; Roger M Engelmann; Maryellen L Giger; George Redmond; Keyvan Farahani; Justin S Kirby; Laurence P Clarke
Journal:  J Med Imaging (Bellingham)       Date:  2016-12-19

Review 2.  Management of incidental lung nodules <8 mm in diameter.

Authors:  Marcelo Sánchez; Mariana Benegas; Ivan Vollmer
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 3.  Blood based biomarkers beyond genomics for lung cancer screening.

Authors:  Samir M Hanash; Edwin Justin Ostrin; Johannes F Fahrmann
Journal:  Transl Lung Cancer Res       Date:  2018-06

Review 4.  Implementation of lung cancer screening: promises and hurdles.

Authors:  Helmut Prosch
Journal:  Transl Lung Cancer Res       Date:  2014-10

5.  Validation of the BRODERS classifier (Benign versus aggRessive nODule Evaluation using Radiomic Stratification), a novel HRCT-based radiomic classifier for indeterminate pulmonary nodules.

Authors:  Fabien Maldonado; Cyril Varghese; Srinivasan Rajagopalan; Fenghai Duan; Aneri B Balar; Dhairya A Lakhani; Sanja L Antic; Pierre P Massion; Tucker F Johnson; Ronald A Karwoski; Richard A Robb; Brian J Bartholmai; Tobias Peikert
Journal:  Eur Respir J       Date:  2021-04-01       Impact factor: 16.671

6.  Characteristics of Ground-Glass Nodules Detected by Low-Dose Computed Tomography as a Regular Health Examination Among Chinese Hospital Employees and Their Parents.

Authors:  Bihan Ouyang; Maoyuan Li; Li Li; Shaohui Liu; Min Li
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

7.  ESR/ERS white paper on lung cancer screening.

Authors:  Hans-Ulrich Kauczor; Lorenzo Bonomo; Mina Gaga; Kristiaan Nackaerts; Nir Peled; Mathias Prokop; Martine Remy-Jardin; Oyunbileg von Stackelberg; Jean-Paul Sculier
Journal:  Eur Radiol       Date:  2015-05-01       Impact factor: 5.315

8.  ESR/ERS white paper on lung cancer screening.

Authors:  Hans-Ulrich Kauczor; Lorenzo Bonomo; Mina Gaga; Kristiaan Nackaerts; Nir Peled; Mathias Prokop; Martine Remy-Jardin; Oyunbileg von Stackelberg; Jean-Paul Sculier
Journal:  Eur Respir J       Date:  2015-04-30       Impact factor: 16.671

9.  Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.

Authors:  Gunter Weiss; Anne Schlegel; Denise Kottwitz; Thomas König; Reimo Tetzner
Journal:  J Thorac Oncol       Date:  2016-08-18       Impact factor: 15.609

Review 10.  Early Detection and Chemoprevention of Lung Cancer.

Authors:  Melissa New; Robert Keith
Journal:  F1000Res       Date:  2018-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.